Press release
Cytomegalovirus (CMV) Infection Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Bio
"Cytomegalovirus (CMV) Infection Pipeline Insight, 2025 [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Cytomegalovirus (CMV) Infection Market.
The Cytomegalovirus (CMV) Infection Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Cytomegalovirus (CMV) Infection Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Cytomegalovirus (CMV) Infection treatment therapies with a considerable amount of success over the years.
*
Cytomegalovirus (CMV) Infection companies working in the treatment market are antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others, are developing therapies for the Cytomegalovirus (CMV) Infection treatment
*
Emerging Cytomegalovirus (CMV) Infection therapies in the different phases of clinical trials are- Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others are expected to have a significant impact on the Cytomegalovirus (CMV) Infection market in the coming years.
*
In May 2025, Kamada Ltd. (NASDAQ: KMDA; TASE: KMDA.TA), a global biopharma company specializing in rare and serious conditions and a leader in specialty plasma-derived therapies, has announced the initiation of a new post-marketing research initiative. This program aims to generate important data highlighting the benefits of CYTOGAM Registered -Kamada's Cytomegalovirus Immune Globulin-for managing cytomegalovirus (CMV) in patients undergoing solid organ transplantation.
*
In March 2025, ACTG, an international clinical trials network dedicated to HIV and infectious diseases, has unveiled encouraging results from a study investigating the impact of treating asymptomatic cytomegalovirus (CMV) in individuals living with HIV. The findings suggest that CMV suppression may enhance immune function and overall physical health. Shared at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco, the results come from study A5383 and were presented as an oral abstract titled, "Asymptomatic CMV Suppression with Letermovir Improves Immunologic and Functional Aging-related Outcomes in Treated HIV.
*
In January 2025, Fortress Biotech, Inc. (Nasdaq: FBIO) and its majority-owned subsidiary, Helocyte, Inc., announced that the first patient has been dosed in a multicenter, randomized, placebo-controlled Phase 2 clinical trial. The study aims to assess the effectiveness of Triplex, a cytomegalovirus (CMV) vaccine, when given to human leukocyte antigen (HLA)-matched related stem cell donors to reduce CMV occurrences in patients undergoing hematopoietic stem cell transplantation (HSCT).
*
In February 2024, A novel mRNA vaccine currently undergoing phase 3 clinical trials demonstrated superior efficacy in stimulating the immune system to combat Cytomegalovirus (CMV) Infection. This experimental mRNA vaccine targeting human cytomegalovirus (CMV), a prevalent virus with potential prenatal transmission, has elicited highly encouraging immune responses compared to other CMV vaccine candidates, as per research conducted by investigators from Weill Cornell Medicine.
Cytomegalovirus (CMV) Infection Overview
Cytomegalovirus (CMV) Infection is a common viral infection caused by the cytomegalovirus, a type of herpes virus. CMV is widespread and can infect people of all ages. In healthy individuals with intact immune systems, CMV infection often causes mild or no symptoms and may go unnoticed. However, in individuals with weakened immune systems, such as those with HIV/AIDS, organ transplant recipients, or infants infected in utero, CMV infection can lead to more severe complications.
Get a Free Sample PDF Report to know more about Cytomegalovirus (CMV) Infection Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight [https://www.delveinsight.com/report-store/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Emerging Cytomegalovirus (CMV) Infection Drugs Under Different Phases of Clinical Development Include:
*
Research programme: antiviral therapeutics TSRL
*
SYN002: Synklino
*
Posoleucel: AlloVir
*
mRNA-1647: Moderna
*
CMV TCR T cell therapy: China Immunotech
*
NPC-21: Nobelpharma
*
HB-101: Hookipa Biotech GmbH
*
Cytomegalovirus immune globulin: Biotest
*
Posoleucel: AlloVir
*
VBI-1501A: VBI Vaccines
*
LTV 20: Lion TCR
*
Maribavir: Shire
*
V160: Merck Sharp & Dohme
*
Maribavir: Takeda
*
Valganciclovir: CSL Behring
*
Brincidofovir: Chimerix
*
Everolimus: Novartis
*
HB-101 vaccine: Hookipa Biotech GmbH
Cytomegalovirus (CMV) Infection Route of Administration
Cytomegalovirus (CMV) Infection pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Intranasal
*
Intrathecal
*
Intravenous
*
Oral
*
Oral/Intravenous
*
Parenteral
*
Subcutaneous
*
Subcutaneous/Intramuscular
*
Transdermal
Cytomegalovirus (CMV) Infection Molecule Type
Cytomegalovirus (CMV) Infection Products have been categorized under various Molecule types, such as
*
Antisense oligonucleotide
*
Gene therapy
*
Hormones
*
Neuropeptides
*
Oligonucleotides
*
Small Molecule
*
Triglyceride
Cytomegalovirus (CMV) Infection Pipeline Therapeutics Assessment
*
Cytomegalovirus (CMV) Infection Assessment by Product Type
*
Cytomegalovirus (CMV) Infection By Stage and Product Type
*
Cytomegalovirus (CMV) Infection Assessment by Route of Administration
*
Cytomegalovirus (CMV) Infection By Stage and Route of Administration
*
Cytomegalovirus (CMV) Infection Assessment by Molecule Type
*
Cytomegalovirus (CMV) Infection by Stage and Molecule Type
DelveInsight's Cytomegalovirus (CMV) Infection Report covers around 20+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Cytomegalovirus (CMV) Infection product details are provided in the report. Download the Cytomegalovirus (CMV) Infection pipeline report to learn more about the emerging Cytomegalovirus (CMV) Infection therapies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key companies in the Cytomegalovirus (CMV) Infection Therapeutics Market include:
Key companies developing therapies for Cytomegalovirus (CMV) Infection are - Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Biotherapeutics, SpyBiotech, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, and others.
Cytomegalovirus (CMV) Infection Pipeline Analysis:
The Cytomegalovirus (CMV) Infection pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Cytomegalovirus (CMV) Infection with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Cytomegalovirus (CMV) Infection Treatment.
*
Cytomegalovirus (CMV) Infection key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Cytomegalovirus (CMV) Infection Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Cytomegalovirus (CMV) Infection market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Cytomegalovirus (CMV) Infection drugs and therapies [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Cytomegalovirus (CMV) Infection Pipeline Market Drivers
*
Increasing Prevalence of Cytomegalovirus (CMV) Infection, increase in Research and developmental Activities are some of the important factors that are fueling the Cytomegalovirus (CMV) Infection Market.
Cytomegalovirus (CMV) Infection Pipeline Market Barriers
*
However, high costs associated with the treatment, lack of healthcare infrastructures and other factors are creating obstacles in the Cytomegalovirus (CMV) Infection Market growth.
Scope of Cytomegalovirus (CMV) Infection Pipeline Drug Insight
*
Coverage: Global
*
Key Cytomegalovirus (CMV) Infection Companies: antiviral therapeutics TSRL, Synklino, AlloVir, Moderna, China Immunotech, Nobelpharma, Hookipa Biotech GmbH, Biotest, AlloVir, VBI Vaccines, Lion TCR, Shire, Merck Sharp & Dohme, Takeda, CSL Behring, Chimerix, Novartis, Hookipa Biotech GmbH, and others
*
Key Cytomegalovirus (CMV) Infection Therapies: Research programme, SYN002, Posoleucel, mRNA-1647, CMV TCR T cell therapy, NPC-21, HB-101, Cytomegalovirus immune globulin, Posoleucel, VBI-1501A, LTV 20, Maribavir, V160, Maribavir, Valganciclovir, Brincidofovir, Everolimus, HB-101 vaccine, and others
*
Cytomegalovirus (CMV) Infection Therapeutic Assessment: Cytomegalovirus (CMV) Infection current marketed and Cytomegalovirus (CMV) Infection emerging therapies
*
Cytomegalovirus (CMV) Infection Market Dynamics: Cytomegalovirus (CMV) Infection market drivers and Cytomegalovirus (CMV) Infection market barriers
Request for Sample PDF Report for Cytomegalovirus (CMV) Infection Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/cytomegalovirus-cmv-infection-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Cytomegalovirus (CMV) Infection Report Introduction
2. Cytomegalovirus (CMV) Infection Executive Summary
3. Cytomegalovirus (CMV) Infection Overview
4. Cytomegalovirus (CMV) Infection- Analytical Perspective In-depth Commercial Assessment
5. Cytomegalovirus (CMV) Infection Pipeline Therapeutics
6. Cytomegalovirus (CMV) Infection Late Stage Products (Phase II/III)
7. Cytomegalovirus (CMV) Infection Mid Stage Products (Phase II)
8. Cytomegalovirus (CMV) Infection Early Stage Products (Phase I)
9. Cytomegalovirus (CMV) Infection Preclinical Stage Products
10. Cytomegalovirus (CMV) Infection Therapeutics Assessment
11. Cytomegalovirus (CMV) Infection Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Cytomegalovirus (CMV) Infection Key Companies
14. Cytomegalovirus (CMV) Infection Key Products
15. Cytomegalovirus (CMV) Infection Unmet Needs
16 . Cytomegalovirus (CMV) Infection Market Drivers and Barriers
17. Cytomegalovirus (CMV) Infection Future Perspectives and Conclusion
18. Cytomegalovirus (CMV) Infection Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=cytomegalovirus-cmv-infection-pipeline-2025-moa-and-roa-insights-clinical-trials-status-and-key-companies-involved-by-delveinsight-merck-sharp-dohme-llc-chimerix-vbi-vaccines-atara-bio]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Cytomegalovirus (CMV) Infection Pipeline 2025: MOA and ROA Insights, Clinical Trials Status, and Key Companies Involved by DelveInsight | Merck Sharp & Dohme LLC, Chimerix, VBI Vaccines, Atara Bio here
News-ID: 4064572 • Views: …
More Releases from ABNewswire
Dynamic Roofing Concepts Offers Roof Replacement in Brandon, FL as Aging Roofs I …
Brandon, FL - Homeowners in Brandon, Florida, are facing increased pressure to replace aging roofs as insurance companies tighten coverage requirements. Dynamic Roofing Concepts provides roof replacement in Brandon, FL [https://www.dynamicroofingconcepts.com/] and has seen increased demand as local homeowners face pressure from insurance companies to replace aging roofs.
In Florida, most homeowners are aware that old roofs are more vulnerable to wind and water damage. Insurance providers have responded by requiring…
How to Know When It's Time for an Exterminator: Evo Foam Pest Control's Expert G …
Not sure when to contact an exterminator? Evo Foam Pest Control explains the common signs of pest problems in Austin and why timely intervention is essential.
Austin, TX - Pest infestations can occur at any time, leaving homeowners in Austin, TX, wondering when it's necessary to call an exterminator Austin TX. With numerous pests, including ants, rodents, and termites, threatening the comfort of homes, it's essential to recognize the signs that…
Palm Coast Pest Control Shows How Eco-Friendly Pest Control Keeps Jupiter, FL Ho …
Discover how Palm Coast Pest Control uses eco-friendly solutions to protect Jupiter, FL homes from pests while maintaining a healthy, chemical-free environment.
Jupiter, FL - As residents of Jupiter, FL, seek effective and sustainable solutions to pest problems, Palm Coast Pest Control stands out as a trusted provider of eco-friendly pest control services. The company has earned a reputation for its commitment to keeping homes safe, healthy, and pest-free while also…
Metro Heat and Air OKC Stands Out for Expertise, Reliability, and Customer Care …
Metro Heat and Air OKC is known for delivering top-notch air conditioning services in Edmond, OK, combining professionalism, trustworthiness, and outstanding customer service.
Edmond, OK - In Edmond, OK, residents seeking reliable air conditioning services turn to Metro Heat and Air OKC, a trusted HVAC contractor [https://www.google.com/maps?cid=12790181814582558152] committed to delivering exceptional comfort solutions. The company has earned a solid reputation in the area for its high level of expertise, dependability, and…
More Releases for CMV
Cytomegalovirus (CMV) Infections Market Massive Growth opportunity Ahead
Introduction
Cytomegalovirus (CMV) is a common herpesvirus that affects people worldwide, often remaining latent in the body and reactivating under immunocompromised conditions. While typically asymptomatic in healthy individuals, CMV can cause severe complications in newborns, transplant recipients, and immunocompromised patients, making it a significant global healthcare burden.
With increasing awareness, advances in antiviral therapies, vaccines under development, and transplant-related CMV management, the CMV infections market is experiencing strong growth. The integration of…
Cytomegalovirus (CMV) Vaccine Market | Exploring Current Trends and Growth Statu …
Cytomegalovirus (CMV) Vaccine Market Outlook and Investment Analysis
What is the current outlook for the Cytomegalovirus (CMV) vaccine market?
The CMV vaccine market is seeing positive growth due to the increasing prevalence of CMV infections globally, particularly in immunocompromised populations such as organ transplant recipients and HIV patients. Moreover, the growing awareness of CMV's impact on newborns has contributed to the push for preventive vaccines. A few vaccines are in advanced clinical…
Cytomegalovirus (CMV) Test Market to Develop Rapidly by 2026
Cytomegalovirus (CMV) is a common virus that occurs widely among the population. In the U.S., 50%-85% of adults have been infected with cytomegalovirus (CMV). Most people who are infected with the virus do not experience any significant symptoms or health problems. CMV testing involves either a measurement of cytomegalovirus antibodies, immune proteins produced in response to CMV exposure, or the detection of the virus itself. CMV is found in many…
Global Commercial Cooking Device Market Forecast 2018-2025 CMV Sharper Finish, Q …
Market study on Global Commercial Cooking Device 2018 Research Report presents a professional and complete analysis of Global Commercial Cooking Device Market on the current market situation.
Report provides a general overview of the Commercial Cooking Device industry 2018 including definitions, classifications, Commercial Cooking Device market analysis, a wide range of applications and Commercial Cooking Device industry chain structure. The 2018's report on Commercial Cooking Device industry offers the global…
Cytomegalovirus (CMV) Market: Size, Status, Opportunity Analysis and Forecasts t …
A new independent 162 page research with title 'Cytomegalovirus (CMV): Opportunity Analysis and Forecasts to 2027' guarantees you will remain better informed than your competition. The study covers geographic analysis that includes regions like North America, Europe or Asia and important players/vendors such as Atara Bio, Biotest AG, Helocyte, Merck & Co., Novartis, Shire, ViraCyte With n-number of tables and figures examining the Cytomegalovirus (CMV) Market, the research gives…
Cytomegalovirus (CMV) Infection Treatment and Diagnosis Market Opportunity Analy …
Cytomegalovirus (CMV) is a virus that belongs to herpes virus family that remain dormant in the human body. CMV infection can occur in people of all ages worldwide. CMV is a communicable disease that spreads through body fluids such as saliva, blood, urine, semen, and breast milk. Presence of CMV infection can be detected by various testing methods based on which the global cytomegalovirus infection treatment and diagnosis market can…
